system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adult, Antibodies, Female, Graft Rejection, Graft Survival, HLA Antigens, Histocompatibility Testing, Humans, Kidney, Kidney Transplantation, Living Donors, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Transplantation, Homologous, Young Adult.
user
Is strength of donor-specific antibodies with the use of Luminex single-antigen beads a reliable predictor of acute rejection in living-relative kidney recipients? Context: Luminex single-antigen assay is a promising technique for determination of donor-specific antibodies (DSAs) in renal transplantation. Serum samples from living-relative renal recipients before and after renal transplantation were examined with the use of Luminex single-antigen assay. The impact of de novo DSAs on the early clinical outcomes of renal allograft was analyzed. Of the 61 patients included, 15 patients (24.6%) presented de novo DSA (4 class I, 4 class II, and 7 both classes) after transplantation, and the average (median) cumulative strength of DSA was 1,283 (range, 0-10,802) mean fluorescence index (MFI) for class I versus 1,324 (range, 0-14,985) MFI for class II (P > .05). Twelve (19.7%) of the 61 patients experienced a clinical/subclinical acute rejection (AR) episode within the 1st 2 years after transplantation. A clinical/subclinical AR episode was diagnosed in 40% of DSA(+) patients and 13.0% of DSA(-) patients (P < .05). DSA(+) patients who developed an AR episode had a higher mean cumulative MFI value (8,118.3 ± 5,287.4; range, 1,785-14,985) than patients who did not develop an AR episode (3,283.7 ± 2,601.0; range, 786-8,113; P < .05). Serum creatinine levels in the DSA(+) group were significantly higher than in the DSA(-) group at 12 and 24 months after transplantation. The graft survival rates at 2 years in the DSA(+) and DSA(-) groups were not different (86.7% vs 91.3%; P > .05).
assistant
Patients with de novo DSAs at high strength may suffer a high risk of developing an AR episode. Therefore, careful monitoring of de novo DSAs with the use of Luminex single-antigen beads may help in early intervention for AR in renal allografts and to minimize renal damage caused by the antibodies. Final Decision: yes